Published in Cogn Behav Neurol on December 01, 2004
Specific impairments in the recognition of emotional facial expressions in Parkinson's disease. Neuropsychologia (2008) 1.17
CBT for the treatment of depression in Parkinson's disease: a promising nonpharmacological approach. Expert Rev Neurother (2008) 0.99
Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment. Neurosci Biobehav Rev (2010) 0.96
Pharmacologic treatment of anxiety disorders in Parkinson disease. Am J Geriatr Psychiatry (2013) 0.88
L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease. Neuroscience (2012) 0.88
Anxiety in Parkinson's disease: identification and management. Ther Adv Neurol Disord (2014) 0.86
The under-recognition of depression in Parkinson's disease. Neuropsychiatr Dis Treat (2006) 0.85
Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease. J Neural Transm (Vienna) (2010) 0.84
Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. Behav Pharmacol (2010) 0.82
A Novel Approach to Treating Anxiety and Enhancing Executive Skills in an Older Adult with Parkinson's Disease. Clin Case Stud (2010) 0.82
Imaging of Dopamine in PD and Implications for Motor and Neuropsychiatric Manifestations of PD. Front Neurol (2013) 0.81
Recognition and management of neuropsychiatric complications in Parkinson's disease. CMAJ (2006) 0.78
Behavioral impairments and serotonin reductions in rats after chronic L-dopa. Psychopharmacology (Berl) (2015) 0.76
Unraveling the Relationship between Motor Symptoms, Affective States and Contextual Factors in Parkinson's Disease: A Feasibility Study of the Experience Sampling Method. PLoS One (2016) 0.75
BEWARE: Body awareness training in the treatment of wearing-off related anxiety in patients with Parkinson's disease: study protocol for a randomized controlled trial. Trials (2015) 0.75
Neuropsychiatric Symptoms in Parkinson's Disease: Beyond Complications. Front Psychiatry (2016) 0.75
Is there room for new non-dopaminergic treatments in Parkinson's disease? J Neural Transm (Vienna) (2012) 0.75
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain (2005) 11.80
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89
Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science (2005) 8.20
Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA (2012) 5.40
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain (2003) 4.24
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
Multifactorial determinants of functional capacity in peripheral arterial disease: uncoupling of calf muscle perfusion and metabolism. J Am Coll Cardiol (2009) 2.81
Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol (2003) 2.81
Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. Pain (2013) 2.58
p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54
Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg (2006) 2.52
Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain (2009) 2.49
A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology (2004) 2.35
Human herpesvirus (HHV)-6 and HHV-7 infections in pregnant women. J Infect Dis (2007) 2.29
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials (2010) 2.24
Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain (2006) 2.23
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord (2007) 2.17
The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion (2007) 2.12
The human immune response to streptococcal extracellular antigens: clinical, diagnostic, and potential pathogenetic implications. Clin Infect Dis (2010) 2.04
Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst (2011) 2.03
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
The motor neuron response to SMN1 deficiency in spinal muscular atrophy. Muscle Nerve (2014) 2.02
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01
High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol (2011) 1.95
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94
High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol (2013) 1.90
Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain (2012) 1.88
Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain (2010) 1.84
Tourette syndrome: evolving concepts. Mov Disord (2011) 1.84
Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx (2006) 1.82
Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol (2004) 1.79
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord (2008) 1.78
Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers. Arch Neurol (2005) 1.77
Health-related quality of life consequences of implantable cardioverter defibrillators: results from MADIT II. Med Care (2007) 1.70
The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol (2006) 1.70
The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis (2011) 1.70
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59
Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. J Am Coll Cardiol (2011) 1.58
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol (2013) 1.56
Cognitive fatigue during a test requiring sustained attention: a pilot study. Mult Scler (2003) 1.53
Congenital infections with human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7). J Pediatr (2004) 1.49
Patterns of late gadolinium enhancement in chronic hemodialysis patients. JACC Cardiovasc Imaging (2008) 1.48
Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45
Chromosomal integration of human herpesvirus 6 is the major mode of congenital human herpesvirus 6 infection. Pediatrics (2008) 1.44
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials (2011) 1.43
On the equivalence of some medical cost estimators with censored data. Stat Med (2007) 1.43
Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther (2011) 1.42
Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res (2011) 1.42
The idiopathic intracranial hypertension treatment trial: design considerations and methods. J Neuroophthalmol (2014) 1.40
Reproducibility and reliability of atherosclerotic plaque volume measurements in peripheral arterial disease with cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2007) 1.40
Pain intensity rating training: results from an exploratory study of the ACTTION PROTECCT system. Pain (2016) 1.39
Declining medication requirement in some patients with advanced Parkinson disease and dementia. Clin Neuropharmacol (2003) 1.38
Human herpesvirus 6 (HHV6) DNA persistence and reactivation in healthy children. J Pediatr (2004) 1.37
Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol (2011) 1.32
Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology (2012) 1.31
Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry (2008) 1.27
Direct estimation of the area under the receiver operating characteristic curve in the presence of verification bias. Stat Med (2009) 1.23
Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol (2013) 1.22
Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve (2013) 1.20
Sex differences in outcome after mild traumatic brain injury. J Neurotrauma (2010) 1.18
PANDAS: horse or zebra? Neurology (2009) 1.14
The immunobiology of Tourette's disorder, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus, and related disorders: a way forward. J Child Adolesc Psychopharmacol (2010) 1.13
The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord (2008) 1.12
Normal pressure hydrocephalus: diagnosis and treatment. Curr Neurol Neurosci Rep (2008) 1.11
A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol (2010) 1.10
Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology (2012) 1.10
If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemp Clin Trials (2011) 1.08
Long-term fetal cell transplant in Huntington disease: stayin' alive. Neurology (2007) 1.08
Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol (2011) 1.08
Association of plastin 3 expression with disease severity in spinal muscular atrophy only in postpubertal females. Arch Neurol (2010) 1.06
Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia. Arch Neurol (2007) 1.06
Moving from PANDAS to CANS. J Pediatr (2011) 1.06
Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. Am J Hum Genet (2012) 1.05
Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol (2006) 1.04
Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer. Radiat Oncol (2013) 1.04
Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry (2008) 1.04
Characteristics and acquisition of human herpesvirus (HHV) 7 infections in relation to infection with HHV-6. J Infect Dis (2006) 1.03
Epidermal nerve fiber density, axonal swellings and QST as predictors of HIV distal sensory neuropathy. Muscle Nerve (2004) 1.02
Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord (2007) 1.01
Development and testing of the Parkinson's disease quality of life scale. Mov Disord (2003) 1.01
Research participants' "irrational" expectations: common or commonly mismeasured? IRB (2013) 1.00
Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol (2013) 1.00
Obesity does not increase complications after anatomic resection for non-small cell lung cancer. Ann Thorac Surg (2007) 0.99
Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Mov Disord (2003) 0.99
Potential role of ultra-sensitive estradiol assays in estimating the risk of breast cancer and fractures. Steroids (2008) 0.98
A randomized trial comparing long-term and short-term use of umbilical venous catheters in premature infants with birth weights of less than 1251 grams. Pediatrics (2006) 0.97
Movement disorders after stroke in adults: a review. Tremor Other Hyperkinet Mov (N Y) (2012) 0.97
Diagnostic odyssey of patients with myotonic dystrophy. J Neurol (2013) 0.97
Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology (2007) 0.97
Psychosocial risk factors for postherpetic neuralgia: a prospective study of patients with herpes zoster. J Pain (2005) 0.97
The management of tics. Mov Disord (2009) 0.96
The relationship between uric acid levels and Huntington's disease progression. Mov Disord (2010) 0.96